share_log

Evercore ISI Group Downgrades Spero Therapeutics to In-Line, Maintains Price Target to $5

Evercore ISI Group Downgrades Spero Therapeutics to In-Line, Maintains Price Target to $5

Evercore ISI集團將Spero Therapeutics評級下調至持平,維持目標價格爲5美元
Benzinga ·  2024/12/20 19:40  · 評級/大行評級

Evercore ISI Group analyst Josh Schimmer downgrades Spero Therapeutics (NASDAQ:SPRO) from Outperform to In-Line and maintains the price target from $5 to $5.

Evercore ISI Group 分析師Josh Schimmer將Spero Therapeutics(納斯達克:SPRO)從「超出市場表現」評級下調至「持平」,並維持價格目標從$5到$5。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論